soligenix announces appointment of marco maria brughera to its board of directors  soligenix home  join newsletter  careers  contact us search news  events october   soligenix announces appointment of marco maria brughera to its board of directors princeton nj – october   – soligenix inc otcqb sngx soligenix or the company a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need announced today the appointment of marco maria brughera dvm global head of the rare disease franchise for sigmatau spa to its board of directors “we are pleased to welcome dr brughera to the soligenix board” stated christopher j schaber phd president and chief executive officer of soligenix “as soligenix looks to advance its pipeline we intend to leverage dr brughera’s extensive experience in research and development portfolio optimization and business development we believe his outstanding record of achievement will add significantly to our already diverse and experienced board of directors and management team  we look forward to his contributions to our future success particularly as we move forward with our infectious disease and biodefense programs including the development of orbeshield™ in gi ars under our recent barda and niaid contract awards of up to m and m respectively” since january  dr brughera has held several positions for the sigmatau group including corporate research and development managing director of sigmatau spa president of sigmatau research and board member of sigmatau pharmaceuticals  from  to  dr brughera served as the vice president of preclinical development at nerviano medical sciences nms a pharmaceutical oncologyfocused integrated discovery and development company  he also served as the managing director at accelera an independent contract research organization with the nms group  from  to  dr brughera held several senior level positions in the areas of discovery and development toxicology with pharmacia and pfizer prior to  he held various positions at pharmacia  upjohn and farmitalia carlo erba spa an italian pharmaceutical company he currently serves on the board of gentium spa  dr brughera earned his degree in veterinary medicine from the university of milan and is a european registered toxicologist about soligenix inc soligenix is a clinical stage biopharmaceutical company developing products to treat serious inflammatory diseases where there remains an unmet medical need as well as developing several biodefense vaccines and therapeutics soligenix is developing proprietary formulations of oral bdp beclomethasone dipropionate for the preventiontreatment of gastrointestinal disorders characterized by severe inflammation including pediatric crohn’s disease sgx acute radiation enteritis sgx and chronic graftversushost disease orbec® as well as developing its novel innate defense regulator idr technology sgx for the treatment of oral mucositis through its biodefense division soligenix is developing countermeasures pursuant to the biomedical advanced research and development authority barda strategic plan of  for inclusion in the us government’s strategic national stockpile soligenix’s lead biodefense products in development are a recombinant subunit vaccine called rivax™ which is designed to protect against the lethal effects of exposure to ricin toxin and velothrax™ a vaccine against anthrax exposure rivax™ has been shown to be well tolerated and immunogenic in two phase  clinical trials in healthy volunteers both rivax™ and velothrax™ are currently the subject of a  million national institute of allergy and infectious diseases niaid grant supporting development of soligenix’s new vaccine heat stabilization technology known as thermovax™  soligenix is also developing orbeshield™ for the treatment of gastrointestinal acute radiation syndrome gi ars under a barda contract award valued up to  million and a niaid contract award valued up to  million orbeshield™ has previously demonstrated statistically significant preclinical survival results in a canine model of gi ars funded by the niaid  recently soligenix announced a worldwide exclusive collaboration with intrexon corporation that will focus on the joint development of a treatment for melioidosis a high priority biothreat and an area of unmet medical need for further information regarding soligenix inc please visit the company’s website at httpwwwsoligenixcom this press release contains forwardlooking statements that reflect soligenix inc’s current expectations about its future results performance prospects and opportunities including but not limited to potential market sizes patient populations and clinical trial enrollment  statements that are not historical facts such as “anticipates” “estimates” “believes” “intends” “potential” or similar expressions are forwardlooking statements  these statements are subject to a number of risks uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in or implied by these statements  soligenix cannot assure you that it will be able to successfully develop achieve regulatory approval for or commercialize products based on its technologies particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats conducting preclinical and clinical trials of vaccines obtaining regulatory approvals and manufacturing vaccines that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts that it will be able to successfully obtain any further funding to support product development and commercialization efforts including grants and awards maintain its existing grants which are subject to performance enter into any biodefense procurement contracts with the us government or other countries that it will be able to compete with larger and better financed competitors in the biotechnology industry that changes in health care practice third party reimbursement limitations and federal andor state health care reform initiatives will not negatively affect its business or that the us congress may not pass any legislation that would provide additional funding for the project bioshield program  these and other risk factors are described from time to time in filings with the securities and exchange commission including but not limited to soligenix’s reports on forms q and k  unless required by law soligenix assumes no obligation to update or revise any forwardlooking statements as a result of new information or future events   soligenix announces appointment of marco maria brughera to its board of directors soldevadmn october   news go back ← soligenix announces formation of international melioidosis scientific advisory board soligenix to host conference call and webcast discussion on oral mucositis → soligenix announces appointment of marco maria brughera to its board of directors soligenix announces appointment of marco maria brughera to its board of directors oct    et from soligenix inc princeton nj oct   prnewswire  soligenix inc otcqb sngx soligenix or the company a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need announced today the appointment of marco maria brughera dvm global head of the rare disease franchise for sigmatau spa to its board of directors  we are pleased to welcome dr brughera to the soligenix board stated christopher j schaber phd president and chief executive officer of soligenix as soligenix looks to advance its pipeline we intend to leverage dr brugheras extensive experience in research and development portfolio optimization and business development we believe his outstanding record of achievement will add significantly to our already diverse and experienced board of directors and management team  we look forward to his contributions to our future success particularly as we move forward with our infectious disease and biodefense programs including the development of orbeshield™ in gi ars under our recent barda and niaid contract awards of up to m and m respectively since january  dr brughera has held several positions for the sigmatau group including corporate research and development managing director of sigmatau spa president of sigmatau research and board member of sigmatau pharmaceuticals  from  to  dr brughera served as the vice president of preclinical development at nerviano medical sciences nms a pharmaceutical oncologyfocused integrated discovery and development company  he also served as the managing director at accelera an independent contract research organization with the nms group  from  to  dr brughera held several senior level positions in the areas of discovery and development toxicology with pharmacia and pfizer prior to  he held various positions at pharmacia  upjohn and farmitalia carlo erba spa an italian pharmaceutical company he currently serves on the board of gentium spa  dr brughera earned his degree in veterinary medicine from the university of milan and is a european registered toxicologist about soligenix inc soligenix is a clinical stage biopharmaceutical company developing products to treat serious inflammatory diseases where there remains an unmet medical need as well as developing several biodefense vaccines and therapeutics soligenix is developing proprietary formulations of oral bdp beclomethasone dipropionate for the preventiontreatment of gastrointestinal disorders characterized by severe inflammation including pediatric crohns disease sgx acute radiation enteritis sgx and chronic graftversushost disease orbec® as well as developing its novel innate defense regulator idr technology sgx for the treatment of oral mucositis   through its biodefense division soligenix is developing countermeasures pursuant to the biomedical advanced research and development authority barda strategic plan of  for inclusion in the us governments strategic national stockpile soligenixs lead biodefense products in development are a recombinant subunit vaccine called rivax™ which is designed to protect against the lethal effects of exposure to ricin toxin and velothrax™ a vaccine against anthrax exposure rivax™ has been shown to be well tolerated and immunogenic in two phase  clinical trials in healthy volunteers both rivax™ and velothrax™ are currently the subject of a  million national institute of allergy and infectious diseases niaid grant supporting development of soligenixs new vaccine heat stabilization technology known as thermovax™  soligenix is also developing orbeshield™ for the treatment of gastrointestinal acute radiation syndrome gi ars under a barda contract award valued up to  million and a niaid contract award valued up to  million orbeshield™ has previously demonstrated statistically significant preclinical survival results in a canine model of gi ars funded by the niaid  recently soligenix announced a worldwide exclusive collaboration with intrexon corporation that will focus on the joint development of a treatment for melioidosis a high priority biothreat and an area of unmet medical need for further information regarding soligenix inc please visit the companys website at wwwsoligenixcom this press release contains forwardlooking statements that reflect soligenix incs current expectations about its future results performance prospects and opportunities including but not limited to potential market sizes patient populations and clinical trial enrollment  statements that are not historical facts such as anticipates estimates believes intends potential or similar expressions are forwardlooking statements  these statements are subject to a number of risks uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in or implied by these statements  soligenix cannot assure you that it will be able to successfully develop achieve regulatory approval for or commercialize products based on its technologies particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats conducting preclinical and clinical trials of vaccines obtaining regulatory approvals and manufacturing vaccines that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts that it will be able to successfully obtain any further funding to support product development and commercialization efforts including grants and awards maintain its existing grants which are subject to performance enter into any biodefense procurement contracts with the us government or other countries that it will be able to compete with larger and better financed competitors in the biotechnology industry that changes in health care practice third party reimbursement limitations and federal andor state health care reform initiatives will not negatively affect its business or that the us congress may not pass any legislation that would provide additional funding for the project bioshield program  these and other risk factors are described from time to time in filings with the securities and exchange commission including but not limited to soligenixs reports on forms q and k  unless required by law soligenix assumes no obligation to update or revise any forwardlooking statements as a result of new information or future events source soligenix inc related links httpwwwsoligenixcom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more oct    et preview soligenix to host conference call and webcast discussion on oral mucositis oct    et preview soligenix announces formation of international melioidosis scientific advisory board my news release contains wide tables view fullscreen read more jun    et dusquetide technology platform to be presented at the  drug jun    et soligenix receives additional niaid funding to advance jun    et complete efficacy and longterm followup safety results from looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search page not found  thestreet action alerts plus access aapjim cramers best stocks for charitable trust portfoliomost recent trade alert investing rules trading commandments real money access rm rules of investingjim cramers best stocks for  commandmentsstressed out stockscramers blog cramer mad money etfs futures markets much more banksbiotechretailtechpersonal financeretirementfinancial advisor centerhow to spendoptionsfixed incomevideo privacy policyterms of use  thestreet inc all rights reserved djia nasdaq sp  market data updated sign in your memberships your account account preferences alerts newsletters subscribe logout subscribe access insights and guidance from our wall street pros find the product thats right for you action alerts plus action alerts options daily swing trade income seeker quant ratings real money real money pro stocks under  top stocks trifecta stocks real money pro portfolio chairmans club compare all chatter on the street page not found sorry the page youre looking for is not available you might want to try our homepage our most popular stories  thestreet inc all rights reservedaction alerts plus is a registered trademark of thestreet inc compare brokers sngx marco maria brughera insider trades for soligenix inc bulletin investor alert new york markets open in market snapshot analyst ratings expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close soligenix inc nasdaq sngx go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus soligenix inc market closed  quotes are delayed by  min jul    pm sngx quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual marco maria brughera dr marco m brughera is independent director at soligenix inc chief executive officer at prassis  istituto di ricerche sigmatau spa president at sigmatau research switzerland sa president  chief executive officer at tecnogen spa chief executive officer at sigma tau pharma ltd managing directorresearch  development at sigmatau industrie farmaceutiche riunite spa and president at sigmatau pharmaceuticals inc he is on the board of directors at lees pharmaceutical holdings ltd and soligenix inc dr brughera was previously employed as managing directorresearch  development by sigmatau finanziaria spa he also served on the board at gentium spa sigma tau rare diseases sa and sigmatau pharmaceuticals inc he received his doctorate degree from the university of milan transactions date shares transaction value copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr christopher j schaber chairman president  chief executive officer ms karen r krumeich chief financial officer  senior vice president dr oreola donini chief scientific officer  senior vice president dr richard c straube chief medical officer  senior vice president dr rasappa arumugham vice presidentbiopharmaceutical development mr adam t rumage vpregulatory affairs  project management dr robert joseph rubin independent director mr gregg anthony lapointe independent director dr jerome b zeldis independent director mr keith l brownlie independent director dr marco maria brughera independent director log in  am edt july   marketstatecountryus new york pre marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ahuawei smartphone shipments jump revenue soars afoxtons profit falls  as brexit hits market ajust eat profit jumps  ups revenue guidance aftse  steady as astrazeneca plunges diageo surges adaily mail revenue up warns on some markets aweir profit jumps on strong oil and gas showing asmith  nephew profit rises on track for targets aspains unemployment rate drops to  avolkswagen profit up lifts sales guidance athomas cook loss halves backs fullyear guidance alloyds profit narrows on £ bln compensation bill aairbus profit down  on lower plane deliveries atate  lyle profit ahead backs fullyear guidance aoil majors sustain profits despite crudes slide aastrazenecas mystic cancer drug trial fails aastrazenecas mystic lung cancer trial fails to meet endpoint aastrazeneca tumbles  after decline in quarterly revenue adeutsche bank shares falls  after earnings report aanglo american up  after dividend reinstatement agermanys dax opens  lower at  loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  marco maria brughera profile  free company director check company director check uk company directors reports free company director check company director search advanced search uk    england    greater london    city of london    farringdon without    farringdon without  eca  marco maria brughera  holborn viaduct london director list of companies where marco maria brughera was involved free company director check marco maria brughera worked in sigmatau pharma limited as a director active directorships  resigned directorships  closed directorships  total directorships  personal history sigmatau pharma limited  april    july  director details marco maria brughera  holborn viaduct london nationality italian postcode eca dy country of residence italy potentially the same person marco maria brughera  holborn viaduct london previous appointments sigmatau pharma limited click to show map marco maria brughera worked as a director in sigmatau pharma limited resigned company address sigmatau pharma limitedco baxalta uk limited  kingston road staines united kingdom tw lg company documents company documents   buy documents buy documents another directors in sigmatau pharma limited name address amanda miller london marco codella andrea montevecchi bologna antonio nicolai roma giuseppe codonesu lesley sharon roche basingstoke michael ford high wycombe massimo mineo london gianemilio nathan yoseph stern milano people with surname brughera angelo brughera   wenlock road london do you want us to keep you updated about changes for this personplease insert your email address date of last update  july  reload the data  company director check companydirectorcheckcom contact us disclaimer listing policy companydirectorcheckcom provides details of current and historic companies including registration details accounts and director information registered across england scotland wales and northern ireland when a limited company is incorporated it has a legal obligation under the companies act to make all business details available for public inspection including registration details accounts and director information we use this data to generate the records published on our websites these records are publicly available from the registrar of companies companies house uk in certain cases the registry trust and from various other company data websites limited company data is not subject to the data protection act there are no data protection regulations related to limited company data and no authorisations or permissions required with regards to its publication soligenix announces appointment of marco maria brughera to its board of directors employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       soligenix sngxob announces appointment of marco maria brughera to its board of directors tweet   am princeton nj oct   prnewswire  soligenix inc otcqb sngx soligenix or the company a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need announced today the appointment of marco maria brughera dvm global head of the rare disease franchise for sigmatau spa to its board of directors we are pleased to welcome dr brughera to the soligenix board stated christopher j schaber phd president and chief executive officer of soligenix as soligenix looks to advance its pipeline we intend to leverage dr brugheras extensive experience in research and development portfolio optimization and business development we believe his outstanding record of achievement will add significantly to our already diverse and experienced board of directors and management team we look forward to his contributions to our future success particularly as we move forward with our infectious disease and biodefense programs including the development of orbeshield in gi ars under our recent barda and niaid contract awards of up to m and m respectively since january  dr brughera has held several positions for the sigmatau group including corporate research and development managing director of sigmatau spa president of sigmatau research and board member of sigmatau pharmaceuticals from  to  dr brughera served as the vice president of preclinical development at nerviano medical sciences nms a pharmaceutical oncologyfocused integrated discovery and development company he also served as the managing director at accelera an independent contract research organization with the nms group from  to  dr brughera held several senior level positions in the areas of discovery and development toxicology with pharmacia and pfizer prior to  he held various positions at pharmacia  upjohn and farmitalia carlo erba spa an italian pharmaceutical company he currently serves on the board of gentium spa dr brughera earned his degree in veterinary medicine from the university of milan and is a european registered toxicologistabout soligenix incsoligenix is a clinical stage biopharmaceutical company developing products to treat serious inflammatory diseases where there remains an unmet medical need as well as developing several biodefense vaccines and therapeutics soligenix is developing proprietary formulations of oral bdp beclomethasone dipropionate for the preventiontreatment of gastrointestinal disorders characterized by severe inflammation including pediatric crohns disease sgx acute radiation enteritis sgx and chronic graftversushost disease orbec® as well as developing its novel innate defense regulator idr technology sgx for the treatment of oral mucositis through its biodefense division soligenix is developing countermeasures pursuant to the biomedical advanced research and development authority barda strategic plan of  for inclusion in the us governments strategic national stockpile soligenixs lead biodefense products in development are a recombinant subunit vaccine called rivax which is designed to protect against the lethal effects of exposure to ricin toxin and velothrax a vaccine against anthrax exposure rivax has been shown to be well tolerated and immunogenic in two phase  clinical trials in healthy volunteers both rivax and velothrax are currently the subject of a  million national institute of allergy and infectious diseases niaid grant supporting development of soligenixs new vaccine heat stabilization technology known as thermovax soligenix is also developing orbeshield for the treatment of gastrointestinal acute radiation syndrome gi ars under a barda contract award valued up to  million and a niaid contract award valued up to  million orbeshield has previously demonstrated statistically significant preclinical survival results in a canine model of gi ars funded by the niaid recently soligenix announced a worldwide exclusive collaboration with intrexon corporation that will focus on the joint development of a treatment for melioidosis a high priority biothreat and an area of unmet medical needfor further information regarding soligenix inc please visit the companys website at wwwsoligenixcom this press release contains forwardlooking statements that reflect soligenix incs current expectations about its future results performance prospects and opportunities including but not limited to potential market sizes patient populations and clinical trial enrollment statements that are not historical facts such as anticipates estimates believes intends potential or similar expressions are forwardlooking statements these statements are subject to a number of risks uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in or implied by these statements soligenix cannot assure you that it will be able to successfully develop achieve regulatory approval for or commercialize products based on its technologies particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats conducting preclinical and clinical trials of vaccines obtaining regulatory approvals and manufacturing vaccines that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts that it will be able to successfully obtain any further funding to support product development and commercialization efforts including grants and awards maintain its existing grants which are subject to performance enter into any biodefense procurement contracts with the us government or other countries that it will be able to compete with larger and better financed competitors in the biotechnology industry that changes in health care practice third party reimbursement limitations and federal andor state health care reform initiatives will not negatively affect its business or that the us congress may not pass any legislation that would provide additional funding for the project bioshield program these and other risk factors are described from time to time in filings with the securities and exchange commission including but not limited to soligenixs reports on forms q and k unless required by law soligenix assumes no obligation to update or revise any forwardlooking statements as a result of new information or future events source soligenix inc help employers find you check out all the jobs and post your resume read at biospacecom related news fda grants soligenix sngxob orphan drug designation for sgx for treatment of acute radiation syndrome investor calls on xenoport inc xnpt to change focus oust ceo soligenix sngxob awarded national institute of allergy and infectious diseases niaid contract valued up to  million for the development of orbeshield in gi ars glide pharma appoints bryan g morton as chairman and announces board changes soligenix sngxob awarded biomedical advanced research and development authority barda contract valued up to  million for advanced development of orbeshield in gi ars simcere pharmaceutical group hires former glaxosmithkline gsk rd exec embroiled in data scandal soligenix sngxob appoints oreola donini phd as vice president of preclinical research and development vivus inc vvus president to quit oct  soligenix sngxob completes phase  clinical study with sgx for the treatment of pediatric crohns disease bayer ag baynde snags pfizer inc pfe exec for head of healthcare post please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • soligenix   • biotechpharma  personnel                 login  evaluate retrieving data you are a  user the feature you are trying to access  subscribers please register to access this feature or log in if you are a subscriber or if you have already registered please click the following link to register and submit an upgrade request so that a member of our sales team can contact you to discuss your requirements register and upgrade please click the request upgrade button to log your details so that a member of our sales team can contact you to discuss your additional requirements your request to access this feature is pending you have already logged a callback request a member of our team will contact you to discuss your access level view my contact details   this feature is not yet available we have already attempted to contact you following your recent request we will try and call you again shortly but in the meantime please check that your contact details are correct and up to date or if you prefer please contact us view my contact details   contact us retrieving ep vantage brings a fresh view on pharma and biotech with incisive daily analysis powered by evaluate ltd you are a subscriber to the full evaluate ltd service click here to login to the subscribers welcome page        no i do not want to log in now dont remind me again you are currently accessing our secondary server although the site contains up to date data some features are unfortunately not available on the secondary server we apologise for any inconvenience this may cause close ecommerce support if you would prefer to speak to a member of our sales team please call us on     alternatively if you are experiencing problems with an existing order a member of our support team will be happy to assist you call     telephone lines are open mon  fri am  pm london time alternatively send an email to chrissiepennockevaluategroupcom close shopping cart fetching cart contents please wait please register your details with us to complete your purchase or click login if you have already registered with us     close report summary retrieving report details share with a colleague     show report description this report has already been purchased and is available to view now or you may purchase the report again for the latest data you have already purchased this report but a problem is preventing you from accessing the information it contains before calling a member of our support team please attempt to regenerate your report again from your purchase history page add this item to my basket or regenerate for free this item has already been added to your cart regenerating content    please complete the fields below recipients email    required your email    required your name    required optional message sending email   an email has been successfully sent return to report summary failed to send return to report summary failed to retrieve further details for this product the item has successfully been added to your cart your selected reports will remain in your cart for  days you have succeeded in buying the reports however you havent generated your reports yet please go to purchase history to generate your ordered reports now site maintenance planned the website will be unavailable on thursday  april from pm for routine maintenance please save your work and log out before then remind me later x got it marco maria brughera dvm executive profile  biography  bloomberg july    am et pharmaceuticals company overview of sigmatau pharma limited uk snapshotpeople  overviewboard memberscommittees executive profile marco maria brughera dvmchief executive officer and global head sigmatau pharma limited ukagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background dr marco maria brughera dvm serves as the chief executive officer and global head at sigmatau pharma limited uk mr brughera has been the managing director of corporate research  development at sigmatau group since joining in  and also serves as its chief executive officer and global head of the rare disease business unit at sigmatau he manages the global rd portfolio including several programs in research preclinical clinical and registration stages  he serves as the chairman and president of sigmatau pharmaceuticals inc and sigmatau research he has over  years of experience and management in research and development and operations in the healthcare industry he joining sigmatau in  as managing director of its corporate rd division from  to  he served as the vice president of preclinical development at nerviano medical sciences nms a pharmaceutical oncologyfocused integrated discovery and development company he took charge of sigmatau’s rare disease franchise in october  he also served as the managing director at accelera an independent contract research organization with the nms group from  to  he held several senior level positions in the areas of discovery and development toxicology with pharmacia and pfizer prior to  he held various positions at pharmacia  upjohn and farmitalia carlo erba spa an italian pharmaceutical company he has been a non executive director at lees pharmaceutical holdings ltd since december   he has been a director of fennec pharmaceuticals inc since august   and soligenix inc since october   he serves on the board of biopharmaceutical company he served as a member of the board of directors at gentium spa from december  to january   he has authored more than  publications dr brughera earned his degree in veterinary medicine from the university of milan and accreditations from institutions including the thunderbird school of global management he is a european registered toxicologistread full background corporate headquarters amberley housewindsor berkshire sl dnunited kingdomphone    fax     board members memberships presentdirectorsoligenix incpresentnonexecutive directorlees pharmaceutical holdings limitedpresentdirectorfennec pharmaceuticals inc education unknownother education universita degli studi di milano other affiliations soligenix incfennec pharmaceuticals incuniversita degli studi di milanolees pharmaceutical holdings limitedgentium spa annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact sigmatau pharma limited uk please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close